Clinical Policy: Ventricular Assist Devices

Reference Number: NC.CP.MP.46 Coding Implications
Date of Last Revision: 04/22 Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

A ventricular assist device (VAD) is a mechanical pump that helps a person's heart that is too weak to pump blood through the body. The VAD is designed to provide sufficient blood flow to the damaged or diseased heart. It is sometimes referred to as a "bridge to transplant" since it can help a patient survive until a heart transplant can be performed.

Policy/Criteria

I. It is the policy of Carolina Complete Health that all FDA approved VADs, when used according to their FDA labeled indications (including body size recommendations), are considered **medically necessary** when meeting the following:

A. For implantable VADs, none of the following contraindications:

1 Active, potentially life-threatening, malignancy (except when transplant is done for a cure);

1. Irreversible renal or hepatic dysfunction, severe obstructive pulmonary disease, or other systemic disease with multi-organ involvement;
2. Untreatable dysfunction of another major organ system;
3. A pattern of demonstrated noncompliance or lack of sufficient care-giver support which would place a VAD at serious risk of failure;

B. Has one of the following indications:

1. Member is post-cardiotomy for support of blood circulation;
2. As a bridge to transplant for members who are awaiting heart transplant and not expected to survive until a donor heart can be obtained;
3. As destination therapy for members with end-stage heart failure (NYHA Class IV end-stage left ventricular failure for at least 90 days with a life expectancy of < 2 years) who are ineligible for heart transplant due to age or co-morbidities and all of the following:

a. Meets one of the following:

i. Failure to respond to optimal medical management (including beta-blockers and ACE inhibitors if tolerated) for at least 45 of the last 60 days, or

ii. Has been balloon pump-dependent for ≥7 days, or

iii. IV inotrope-dependent for ≥14 days, *and*

iv. Cardiac Index (CI) <2.2 L/min/m2, while not on inotropes and meet one of the following criteria:

1) No response to optimal medical management (including beta-blockers and ACE inhibitors, if tolerated), for at least 45 out of the last 60 days;
2) Presence of advanced heart failure for at least 14 days with dependence on an intra-aortic balloon pump (IABP) or similar temporary mechanical circulatory support for at least 7 days;

b. Left ventricular ejection fraction (LVEF) < 25%, *and*

c. Functionally limited with a peak oxygen consumption of ≤14 ml/kg/min unless balloon pump- or inotrope-dependent, or physically unable to perform the test.

II. Pediatric-specific VADs are considered **medically necessary** under the FDA Humanitarian Device Exemption (HDE) guidelines for the following device:

A. Berlin Heart EXCOR® Pediatric VAD as a bridge to heart transplant when meeting the following criteria:

1. Age ≤ 16 years, and
2. Severe isolated left ventricular or biventricular dysfunction, and
3. Is a candidate for heart transplant and requires circulatory support.

III. Any requests for VADs not meeting the above criteria will be considered **not medically necessary**.

Note: HDE is granted by FDA. A Humanitarian Use Device (HUD) is a device that is intended to benefit patients in the treatment or diagnosis of a disease or condition that affects fewer than 4,000 individuals in the United States annually. An HUD may only be used in facilities that have established a local institutional review board to supervise clinical testing of devices and after an IRB has approved the use of the device to treat or diagnose the specific disease.

Background

VADs have shown beneficial effects on myocardial function through improvement in myocardial contractile performance; reversal of down regulation of beta-receptors seen in heart failure (HF), with restoration in the ability of the heart to respond to the inotropic effects of sympathetic stimulation; and normalization of chamber geometry, and reduction of myocardial fibrosis, hypertrophy, and disruption in cytoskeletal proteins.

This suggests that failing human myocytes have the capability of undergoing beneficial functional and electrophysiologic changes and an increase in contractile strength in the presence of hemodynamic unloading and improved neurohumoral and circulatory derangements. This remodeling generally is complete by about 40 days, with evidence of clinical benefit and an improvement in quality of life.

Since 2000, there have been improved outcomes in VAD implantation in the pediatric population. Early experience involved the most critically ill children who often were near death at the time of VAD implantation. More recently, centers' increasing experience with the surgical techniques, timing, and postoperative care; the use of more long-term devices over time; and refinements in patient selection, have resulted in improved outcomes despite the increasing use of VADs in smaller and more complex patients. Further study is warranted to optimize criteria for pediatric patient and device selection.

In one study reported by Blume, et al, 86% of pediatric patients who received a VAD were successfully bridged to transplantation from 2000 to 2003. Prior to 2000, only 63% of pediatric patients were successfully bridged to transplantation. The subgroups of patients with congenital heart disease and in smaller, younger patients, who rarely are large enough for most long-term assist devices, did not have as successful applications as the rest of the population.

A prospective multi-institutional investigational device exemption trial compared patients with the Berlin Heart EXCOR with a control group supported on extracorporeal membrane oxygenation (ECMO). Between May 2009 and December 2010, a total of 48 patients ≤16 years of age met the inclusion criteria and were separated into 2 cohorts according to body surface area (cohort 1, <0.7 m2; cohort 2, ≥0.7 m2) with 24 patients in each group. The median survival time for cohorts 1 and 2 (>174 and 144 days, respectively) far exceeded that of ECMO (cohort 1, 13 days; cohort 2, 10 days; *P*<0.001 by log-rank test). Based on the results of this trial, the Berlin Heart EXCOR was granted HDE approval as a device to provide long-term mechanical circulatory support as a bridge to cardiac transplantation in children with severe left or biventricular dysfunction. [19]

American College of Cardiology Foundation/American Heart Association
Nondurable mechanical circulatory support including the use of a percutaneous and extracorporeal ventricular assist device is reasonable as a 'bridge to recovery'. [17]

American Heart Association[24]
The most recent American Heart Association scientific statement suggests placement of temporary MCS (mechanical circulatory support) devices for patients with longer expected recovery times in the case of cardiogenic shock as "a bridge to recovery, bridge to transplantation or a bridge to decision strategy".

National Health Service
This organization currently funds the use of long-term VADs as bridge-to-transplant to support heart transplant candidates who are too unwell to undergo the procedure or are unlikely to survive in a good clinical state until a suitable donor heart becomes available. [18]

Coding Implications
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
33975	Insertion of ventricular assist device; extracorporeal, single ventricle
33976	Insertion of ventricular assist device; extracorporeal, biventricular
33977	Removal of ventricular assist device; extracorporeal, single ventricle
33978	Removal of ventricular assist device; extracorporeal, biventricular
33979	Insertion of ventricular assist device, implantable intracorporeal, single ventricle
33980	Removal of ventricular assist device, implantable intracorporeal, single ventricle
33981	Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s), single or each pump
33982	Replacement of ventricular assist devices pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass
33983	Replacement of ventricular assist devices pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass
33990	Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; arterial access only
33991	Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; both arterial and venous access, with transseptal puncture
33992	Removal of percutaneous ventricular assist device at separate and distinct session from insertion

HCPCS Codes	Description
Q0478	Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
Q0479	Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0480	Driver for use with pneumatic ventricular assist device, replacement only
Q0481	Microprocessor control unit for use with electric ventricular assist device, replacement only
Q0482	Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only
Q0483	Monitor/display module for use with electric ventricular assist device, replacement only
Q0484	Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0485	Monitor control cable for use with electric ventricular assist device, replacement only
Q0486	Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only

Q0487	Leads (pneumatic/electrical) for use with any type of electric/pneumatic ventricular assist device, replacement only
Q0488	Power pack base for use with electric ventricular assist device, replacement only
Q0489	Power pack base for use with electric/pneumatic ventricular assist device, replacement only

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

ICD-10-CM Code	Description
I50.1	Left ventricular failure, unspecified
I50.20	Unspecified systolic (congestive) heart failure
I50.82	Biventricular heart failure
I50.84	End stage heart failure
I50.9	Heart failure, unspecified
I97.0	Post-cardiotomy syndrome
Z94.1	Heart transplant status
Z95.811	Presence of heart assist device

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy adapted for use by North Carolina Health Plan (Carolina Complete Health), per state feedback and requirements: removed contraindication of life expectancy in the absence of heart disease of ≤ 2 years; replaced contraindication of malignancy within 5 years with "active, potentially life-threatening malignancy;" added contraindication of "untreatable significant dysfunction of another major organ system."	06/19	06/19
Annual review completed. No changes to policy content.	04/21	04/21
Annual review completed. Changed "review date" in the header to "Date of Last Revision" and "Date" in the revision log header to "Revision Date." Added "Cardiac Index (CI) <2.2 L/min/m^2, while not on inotropes and meet one of the following criteria: 1. No response to optimal medical management (including beta-blockers and ACE inhibitors, if tolerated, for at least 45 out of the last 60 days; 2. Presence of advanced heart failure for at least 14 days with dependence on an intra-aortic balloon pump (IABP) or similar temporary mechanical circulatory support for at least 7 days" to Policy/Criteria I.B.4 to reflect update to NCD Ventricular Assist Devices 20.9.1 per CMS. Background updated with most recent AHA scientific statement regarding placement of MCS (mechanical circulatory support) devices with no impact on criteria.	4/22	4/22

References

1. Birks EJ. Intermediate- and long-term mechanical circulatory support. UpToDate. www.uptodate.com. Updated July 8, 2020. Accessed January 4, 2022.
2. Blume ED, Naftel DC, Bastardi HJ, et al. Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study. *Circulation*. 2006;113(19):2313-2319. doi:10.1161/CIRCULATIONAHA.105.577601
3. National coverage determination: Ventricular assist device (20.9.1). Centers for Medicare and Medicaid Services Web site: https://www.cms.gov/medicare-coverage-database. Effective December 1, 2020. Accessed January 6, 2022.
4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*, 37(27). July 2016, p. 2129–2200.
5. Miller LW, Guglin M. Patient selection for ventricular assist devices: a moving target. *J Am Coll Cardiol*. 2013;61(12):1209-1221. doi:10.1016/j.jacc.2012.08.1029
6. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: Executive summary. *J Heart Lung Transplant*. 2013;32(2):157-187.
7. U.S. Food and Drug Administration. FDA approves mechanical cardiac assist device for children with heart failure. Cision Press Release Newswire. https://www.prnewswire.com/news-releases/fda-approves-mechanical-cardiac-assist-device-for-children-with-heart-failure-135752843.html. Published December 16, 2011. Accessed January 7, 2022.
8. U.S. Department of Health & Human Services, FDA. Medical devices: Device approvals and clearances. DeBakey VAD® Child – H030003. https://www.accessdata.fda.gov/cdrh_docs/pdf3/H030003A.pdf. February 2011. Accessed January 7, 2022.
9. U.S. Department of Health & Human Service, FDA. Medical devices: Device approvals and clearances. Berlin Heart EXCOR® Pediatric Ventricular Assist Device (VAD) – H100004. https://www.accessdata.fda.gov/cdrh_docs/pdf10/H100004A.pdf. Published December 2011. Accessed January 7, 2022.
10. Fraser, CD. Berlin Heart's EXCOR® Pediatric Ventricular Assist Device (VAD) receives FDA approval. *Businesswire*. December 16, 2011.
11. Miller, R. FDA panel endorses HDE for Berlin Heart Excor Pediatric VAD. *Heartwire.* July 22, 2011.
12. Drummond A. Biomedical surgical planning for pediatric ventricular assist device (PVAD). Dissertation document for Carnegie Mellon University, Carnegie Institute of Technology. 2008.
13. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol.* 2013;62(16):e147-e239. https://www.jacc.org/doi/full/10.1016/j.jacc.2013.05.019
14. National Health Services Division. The clinical and cost-effectiveness of long-term ventricular assist devices (VADs) as a bridge to transplant in adults. *Health Improvement Scotland.* July 2011.
15. 15. Vanderpluym CJ, Fynn-Thompson F, Blume ED. Ventricular assist devices in children: progress with an orphan device application. *Circulation.* 2014;129(14):1530-1537. doi:10.1161/CIRCULATIONAHA.113.005574

16. Jeevanandam V, Eisen H, Pinto, D. Short-term mechanical circulatory assist devices. UpToDate. www.uptodate.com. Updated September 3, 2020. Accessed January 4, 2022.
17. Yarlagadda VV, Maeda K, Zhang Y, et al. Temporary Circulatory Support in U.S. Children Awaiting Heart Transplantation. *J Am Coll Cardiol*. 2017;70(18):2250-2260. doi:10.1016/j.jacc.2017.08.072
18. Bulic A, Maeda K, Zhang Y, et al. Functional status of United States children supported with a left ventricular assist device at heart transplantation. *J Heart Lung Transplant*. 2017;36(8):890-896. doi:10.1016/j.healun.2017.02.024
19. Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. *Circulation.* 2012;126(22):2648-2667. doi:10.1161/CIR.0b013e3182769a54
20. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail*. 2017;23(8):628-651. doi:10.1016/j.cardfail.2017.04.014
21. Singh RK, Singh TP. Heart failure in children: Management. UpToDate. www.uptodate.com. Updated June 5, 2019. Accessed January 4, 2022.
22. Dipchand AI, Kirk R, Naftel DC, et al. Ventricular Assist Device Support as a Bridge to Transplantation in Pediatric Patients. *J Am Coll Cardiol*. 2018;72(4):402-415. doi:10.1016/j.jacc.2018.04.072
23. Caldeira CCB, Machado RC, Caldeira DCB. Implantation of Short-Term and Long-Term Right Ventricular Assist Devices. *Braz J Cardiovasc Surg*. 2017;32(5):435-437. doi:10.21470/1678-9741-2017-0021
24. Ni hIci T, Boardman HMP, Baig K, Stafford JL, et al. Mechanical assist devices for acute cardiogenic shock. *Cochrane Database of Systematic Reviews* 2020, Issue 6. Art. No.: CD013002. DOI: 10.1002/14651858.CD013002.pub2. Accessed January 13, 2022.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at http://www.cms.gov for additional information.